Developer docs
API playgroundTry for free, no card

Search company profiles

Genovis

Full company profile

uuid000fsc8

Namestring
Genovis
Websiteurl
genovis.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Genovis is a biotechnology company that develops and supplies "SmartEnzymes" used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Founded in 1999, the company operates with a small team (11-50 employees) and is listed as headquartered in Cambridge per available source data, with financial reporting denominated in Swedish kronor. Following an August 2024 strategic divestment of its antibody business to Leinco Technologies, Genovis has refocused its operations on its core enzyme technology segment serving biotech and pharmaceutical R&D and quality-control customers.

The company pursues a horizontal segmentation approach built around a single primary segment, Enzyme Operations, with no product-level architectural details publicly disclosed in the source material. Its go-to-market centers on proprietary enzyme reagents embedded in customer analytical workflows, and its revenue mechanics are not transparently disclosed (no pricing model, no publicly disclosed prices, and no named customers). Strategic activity under CEO Fredrik Olsson has emphasized portfolio reshaping: the 2024 antibody-business divestment, the 2020 acquisition of QED Bioscience, and the announced 2026 acquisition of KPL, indicating an M&A-driven approach to extending the company's specialty reagents footprint beyond its core enzyme offering.

No AI/ML capabilities, app products, public-company listing status, or detailed ownership structure are evidenced in the available source material. Customer logos, geographic split, and total revenue figures are also not disclosed, and the multi-year financial dataset appears corrupted (figures in the trillions), limiting quantitative triangulation of scale.

Short descriptiontext

Genovis develops and supplies proprietary SmartEnzymes used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars, serving biotech and pharmaceutical R&D and QC customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKävlinge, Sweden
HQ citystring
Kävlinge
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
enzyme reagents, antibody characterization, biotherapeutics analysis, monoclonal antibody tools, biotech reagents
Industry3 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology Reagents
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Genovis develops and sells SmartEnzymes, proprietary enzyme reagents used by biopharmaceutical researchers to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Following its August 2024 divestment of its antibody business to Leinco Technologies, the company has refocused exclusively on its core enzyme product line for the biotech and pharmaceutical markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Genovis is a biotechnology company that, following the strategic divestment of its antibody business to Leinco Technologies in August 2024, has refocused its operations on core enzyme products. The available source material does not provide specific product names, product architecture details, or product portfolio listings.

Product and service1 record
1SmartEnzymes
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-08-19
Description

Genovis divested its antibody business to Leinco Technologies Inc. This strategic divestment allows Genovis to focus exclusively on its core enzyme operations. The transaction is intended to enhance profitability and foster growth in the company's primary market segment of enzyme technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NEB is a leading developer and manufacturer of enzymes for molecular biology and protein research, including glycosidases and proteases used to characterize biologics. It is a direct peer to Genovis because both sell engineered enzymes into the same biopharma characterization and protein engineering workflows.

TypeDirect peer
Description

Promega supplies enzymes, reagents, and integrated kits used in protein analysis, biologics characterization, and drug development. It is comparable to Genovis because it sells similar enzyme-based tools to biopharma R&D and QC labs, particularly for antibody and protein characterization.

TypeBroad incumbent
Description

Bio-Techne is a large life-sciences tools company with a deep portfolio of proteases, reagents, and antibodies used in biologics development and quality control. It is comparable as a broad incumbent whose protein and enzyme reagents overlap directly with Genovis's SmartEnzymes in mAb/ADC/biosimilar workflows.

TypeBroad incumbent
Description

Thermo Fisher's Life Sciences Solutions and bioscience reagents businesses sell enzymes, antibodies, and characterization tools across the biopharma value chain. It is a broad incumbent comparable to Genovis because it overlaps in enzymes and biologics characterization, although at vastly greater scale.

TypeBroad incumbent
Description

Sartorius supplies bioprocessing equipment, consumables, and analytical tools used in upstream and downstream biologics manufacturing, including QC. It is comparable to Genovis because biopharma manufacturers often purchase both Sartorius bioprocess tools and Genovis-style characterization enzymes as part of the same workflow.

TypeBroad incumbent
Description

Cytiva supplies resins, columns, instruments, and analytical consumables for bioprocessing and biologics QC. It is comparable as a broad incumbent that touches the same antibody/biosimilar manufacturing and characterization workflows as Genovis's enzyme products.

TypeBroad incumbent
Description

Waters supplies chromatography systems, columns, and software used in protein and biologics characterization, including for mAbs, ADCs, and biosimilars. It is comparable to Genovis because its analytical instruments and consumables address the same characterization workflow that Genovis enzymes support.

TypeBroad incumbent
Description

Agilent provides analytical instruments, columns, and reagents for protein characterization, biopharma QC, and biosimilar analysis. It is comparable as a broad incumbent with overlapping tools in the biologics characterization workflow where Genovis's SmartEnzymes are used.

TypeEmerging player
Description

Codexis engineers novel enzymes and biocatalysts using directed-evolution platforms for pharmaceutical and biopharma applications. It is an emerging player comparable to Genovis because both companies commercialize engineered enzymes for therapeutic and biologics-related applications, though Codexis leans more into biocatalysis for synthesis while Genovis focuses on characterization.

TypeBroad incumbent
Description

Roche Diagnostics sells a broad portfolio of clinical chemistry, immunoassay, and biopharma testing products used in protein and antibody analysis. It is a broad incumbent comparable to Genovis because its CustomBiotech and diagnostics businesses supply tools and reagents to biopharma characterization workflows alongside Genovis's SmartEnzymes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genovis

Biotechnology Reagentsgenovis.com

Genovis develops and supplies proprietary SmartEnzymes used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars, serving biotech and pharmaceutical R&D and QC customers.

What Genovis does

Genovis is a biotechnology company that develops and supplies "SmartEnzymes" used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Founded in 1999, the company operates with a small team (11-50 employees) and is listed as headquartered in Cambridge per available source data, with financial reporting denominated in Swedish kronor. Following an August 2024 strategic divestment of its antibody business to Leinco Technologies, Genovis has refocused its operations on its core enzyme technology segment serving biotech and pharmaceutical R&D and quality-control customers.

The company pursues a horizontal segmentation approach built around a single primary segment, Enzyme Operations, with no product-level architectural details publicly disclosed in the source material. Its go-to-market centers on proprietary enzyme reagents embedded in customer analytical workflows, and its revenue mechanics are not transparently disclosed (no pricing model, no publicly disclosed prices, and no named customers). Strategic activity under CEO Fredrik Olsson has emphasized portfolio reshaping: the 2024 antibody-business divestment, the 2020 acquisition of QED Bioscience, and the announced 2026 acquisition of KPL, indicating an M&A-driven approach to extending the company's specialty reagents footprint beyond its core enzyme offering.

No AI/ML capabilities, app products, public-company listing status, or detailed ownership structure are evidenced in the available source material. Customer logos, geographic split, and total revenue figures are also not disclosed, and the multi-year financial dataset appears corrupted (figures in the trillions), limiting quantitative triangulation of scale.

Genovis firmographics

Firmographics
Name
Genovis
Website
https://genovis.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Genovis develops and supplies proprietary SmartEnzymes used to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, ADCs, and biosimilars, serving biotech and pharmaceutical R&D and QC customers.
Ownership category
akta.pro rank

Genovis industry classification

Industry
Product category
Biotechnology Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Enzyme reagents
  • Antibody characterization
  • Biotherapeutics analysis
  • Monoclonal antibody tools
  • Biotech reagents

Where Genovis is headquartered

Location

Headquarters

HQ city
Kävlinge
HQ country
Sweden
HQ region
Europe

Markets served

Genovis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Genovis product offering

Product offering

Core offering

Genovis develops and sells SmartEnzymes, proprietary enzyme reagents used by biopharmaceutical researchers to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Following its August 2024 divestment of its antibody business to Leinco Technologies, the company has refocused exclusively on its core enzyme product line for the biotech and pharmaceutical markets.

Product overview

Genovis is a biotechnology company that, following the strategic divestment of its antibody business to Leinco Technologies in August 2024, has refocused its operations on core enzyme products. The available source material does not provide specific product names, product architecture details, or product portfolio listings.

Differentiator

Problem solved

Functional benefit

Products and services

  • SmartEnzymes

Companies that use Genovis

Customer profile

Segments1 record

Ideal customer profiles1 record

Genovis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Genovis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Leinco Technologies Inc.majorStrategic or Co-development Partner · 19 August 2024Genovis divested its antibody business to Leinco Technologies Inc. This strategic divestment allows Genovis to focus exclusively on its core enzyme operations. The transaction is intended to enhance profitability and foster growth in the company's primary market segment of enzyme technology.

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Genovis competitors and assessment

Company assessment

Direct peers

  • New England Biolabs (NEB): NEB is a leading developer and manufacturer of enzymes for molecular biology and protein research, including glycosidases and proteases used to characterize biologics. It is a direct peer to Genovis because both sell engineered enzymes into the same biopharma characterization and protein engineering workflows.
  • Promega Corporation: Promega supplies enzymes, reagents, and integrated kits used in protein analysis, biologics characterization, and drug development. It is comparable to Genovis because it sells similar enzyme-based tools to biopharma R&D and QC labs, particularly for antibody and protein characterization.

Broad incumbents

  • Bio-Techne: Bio-Techne is a large life-sciences tools company with a deep portfolio of proteases, reagents, and antibodies used in biologics development and quality control. It is comparable as a broad incumbent whose protein and enzyme reagents overlap directly with Genovis's SmartEnzymes in mAb/ADC/biosimilar workflows.
  • Thermo Fisher Scientific: Thermo Fisher's Life Sciences Solutions and bioscience reagents businesses sell enzymes, antibodies, and characterization tools across the biopharma value chain. It is a broad incumbent comparable to Genovis because it overlaps in enzymes and biologics characterization, although at vastly greater scale.
  • Sartorius AG: Sartorius supplies bioprocessing equipment, consumables, and analytical tools used in upstream and downstream biologics manufacturing, including QC. It is comparable to Genovis because biopharma manufacturers often purchase both Sartorius bioprocess tools and Genovis-style characterization enzymes as part of the same workflow.
  • Cytiva (Danaher): Cytiva supplies resins, columns, instruments, and analytical consumables for bioprocessing and biologics QC. It is comparable as a broad incumbent that touches the same antibody/biosimilar manufacturing and characterization workflows as Genovis's enzyme products.
  • Waters Corporation: Waters supplies chromatography systems, columns, and software used in protein and biologics characterization, including for mAbs, ADCs, and biosimilars. It is comparable to Genovis because its analytical instruments and consumables address the same characterization workflow that Genovis enzymes support.
  • Agilent Technologies: Agilent provides analytical instruments, columns, and reagents for protein characterization, biopharma QC, and biosimilar analysis. It is comparable as a broad incumbent with overlapping tools in the biologics characterization workflow where Genovis's SmartEnzymes are used.
  • Roche Diagnostics: Roche Diagnostics sells a broad portfolio of clinical chemistry, immunoassay, and biopharma testing products used in protein and antibody analysis. It is a broad incumbent comparable to Genovis because its CustomBiotech and diagnostics businesses supply tools and reagents to biopharma characterization workflows alongside Genovis's SmartEnzymes.

Emerging players

  • Codexis: Codexis engineers novel enzymes and biocatalysts using directed-evolution platforms for pharmaceutical and biopharma applications. It is an emerging player comparable to Genovis because both companies commercialize engineered enzymes for therapeutic and biologics-related applications, though Codexis leans more into biocatalysis for synthesis while Genovis focuses on characterization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Genovis social profiles

Digital presence

Genovis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genovis leadership team

Management profile

Number of profiles

Profiles1 record

Genovis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genovis M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genovis

What does Genovis do?

Genovis develops and sells SmartEnzymes, proprietary enzyme reagents used by biopharmaceutical researchers to identify and characterize antibody-based biotherapeutics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and biosimilars. Following its August 2024 divestment of its antibody business to Leinco Technologies, the company has refocused exclusively on its core enzyme product line for the biotech and pharmaceutical markets.

When was Genovis founded?

Genovis was founded in 1999. It employs 51 to 100 people.

Where is Genovis based?

Genovis is headquartered in Kävlinge, Sweden, in the Europe region.

Who are Genovis's main competitors?

Direct peers on record are New England Biolabs (NEB) and Promega Corporation. Broad incumbents are Bio-Techne, Thermo Fisher Scientific, Sartorius AG, Cytiva (Danaher), Waters Corporation, Agilent Technologies and Roche Diagnostics. Codexis is listed as an emerging player.

Does Genovis have an API?

No public API is recorded for Genovis.

What industry is Genovis in?

Genovis's product category is Biotechnology Reagents. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewNOTICE OF EXTRAORDINARY GENERAL MEETING IN Genovis AB (PUBL)Genovis AB will hold an extraordinary general meeting on 8 December 2026 to authorize the board to repurchase and transfer own shares. The proposed resolution allows repurchases up to 10% of shares, with transfers at market terms, and requires a two-thirds majority. The notice also sets record and attendance deadlines.TradingViewGenovis AB (publ) (GENO) Seeks Authority to Repurchase Up to 10% of SharesGenovis will ask shareholders at its 8 December 2026 EGM to authorize the board to repurchase shares, capped at 10% of all shares. The authority would run until the next annual general meeting, with no spending amount or timetable disclosed. Shareholder approval requires two-thirds support of votes cast and shares represented.The future of tradingNOTICE OF EXTRAORDINARY GENERAL MEETING IN Genovis AB (PUBL)Genovis AB will hold an extraordinary general meeting on 8 December 2026 to authorize the board to repurchase and transfer own shares. The proposal allows repurchases up to 10% of shares, with transfers on Nasdaq First North Growth Market or cash. The resolution requires two-thirds majority support.Simply Wall StInsiders Buying Genovis AB (publ.) Might Wish They Invested More, Stock Gains 12%Genovis AB insiders bought shares over the past year, and the stock rose 12% last week, increasing their investment by 29%. Insiders own about 16% of the company, and no sales were recorded. The article suggests insider bullishness but notes risks.Dagens industriGenovis rörelseresultat minskar – omsättningen ökarGenovis, a Swedish biotech company that develops enzymes, antibodies, and reagents for pharmaceutical research and diagnostics, reported Q2 2026 financial results with an EBITDA of 6.8 million SEK compared to 6.0 million SEK in the same period the previous year. The headline indicates that while revenue increased, the operating result decreased. The article appears truncated due to subscription requirements, limiting access to full details.The Mass Spectrometry Web PortalGenovis AB. (6/1/26). "Press Release: Genovis Acquires KPL — Expanding Its Enzyme Platform with a Proprietary Portfolio of Precision Proteases for Protein Analysis".Genovis completed its acquisition of KPL, a Denmark-based protease company, for MDKK 30.5 upfront plus a sales-based earn-out. The deal includes 1,395,587 Genovis shares and a 2% dilution, with the earn-out contingent on MSEK 24.4 in sales by 2029.KplbioKPL ApS Announces Strategic Acquisition by Genovis ABKPL ApS, a Copenhagen-based proteomics enzyme company, announced a strategic acquisition by Genovis AB, completed June 1, 2026. KPL will become a wholly owned subsidiary, retaining its team and product portfolio. The deal aims to expand commercial reach and accelerate next-generation enzyme development.BiostockGenovis acquires Danish enzyme companyGenovis acquired Danish enzyme company KPL, adding recombinant sequencing-grade proteases to its portfolio. The deal involves DKK 30.5 million, with 2% share dilution and an earn-out tied to SEK 24.4 million in sales by March 2029. Further product launches are expected over the coming years.NordiclifescienceGenovis divests antibody business to Leinco TechnologiesGenovis has completed the divestment of its antibody business to Leinco Technologies as part of a strategic review to focus on its core enzyme operations. The transaction allows Genovis to concentrate resources on high-growth areas while enabling Leinco to expand its product portfolio in the antibody market. Financial terms of the deal were not disclosed.GlobeNewswireSelecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune DiseaseSelecta Biosciences and Genovis announced an exclusive licensing agreement to advance Xork, an IgG protease, combined with Selecta's ImmTOR platform. The combination aims to address pre-existing AAV immunity and enable re-dosing, with Selecta paying an upfront fee and Genovis earning milestones and royalties.